Author's Profile

Andrea Gaini

Private Equity Reporter

Andrea Gaini is a London-based private equity reporter at PitchBook, covering the private equity markets in Europe and the Middle East. Andrea started his journalism career in 2019 and has written across finance and business publications including TechRadar and Channel Web. Born and raised in Italy, Andrea holds a postgraduate degree in journalism from Cardiff University.

Andrea Gaini_headshot.JPG

Articles by Andrea Gaini

From padel to volleyball, PE targets increasingly niche sports

As more investment floods into sports, private equity is turning to niche areas for high returns and limited competition
November 4, 2024

European M&A brightens as market conditions improve

Lower interest rates are fuelling a resurgence of M&A activity in Europe
October 31, 2024

Applied Nutrition valued at £350M in London IPO

The IPO is already one of the biggest London listings of the year.
October 24, 2024

Europe’s PE-backed companies see an IPO recovery

Following a tough few years, European PE-backed IPOs showed signs of growth this year.
October 23, 2024

Europe’s Q3 private equity recovery in 4 charts

European PE market is on track for significant yearly growth, with a projected 27.5% increase in deal value and 11.5% in deal count
October 16, 2024

Infrastructure fundraising rebound fails to materialize

In Europe and globally, capital raised towards infrastructure funds has plunged amid growing interest rates.
October 11, 2024

CVC Capital-backed Zabka to raise $1.6B after pricing Warsaw IPO

The deal is set to be the largest in Warsaw in four years
October 10, 2024

PE investment in Europe’s oil, gas continues fall—but big deals remain

PE deal value and count in oil and gas is falling sharply, but large-cap deals are still happening
October 4, 2024

TPG, GIC to acquire energy meter maker Techem in $7.4B deal

The transaction is Europe’s largest PE energy deal this year.
October 1, 2024

Has PE fallen out of love with Europe’s biotech industry?

Data from the last five years shows that investment in biotech is dropping sharply with no signs of recovery.
September 26, 2024